MADRIGAL PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 205.2 USD | -0.81% |
|
-10.70% | -11.29% |
Presenter SpeechNavin Jacob (Analysts)Hello. Welcome to the UBS Global Healthcare Conference. ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
205.2
USD
Average target price
363.9
USD
Spread / Average Target
+77.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.29% | 4.37B | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- MDGL Stock
- News Madrigal Pharmaceuticals, Inc.
- Transcript : Madrigal Pharmaceuticals, Inc. Presents at UBS Virtual Global Healthcare Conference, May-19-2020 02